Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for skin involvement in systemic lupus erythematosus
ChiCTR2400086459Phase 2Recruiting
- Sponsor
- Department of Dermatology, Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by Department of Dermatology, Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: SRI-4 response rate. Started Jul 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2400086459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086459.